Vistagen Therapeutics earnings were -$69.7M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest VTGN earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$16.3M, down 13.9% from last quarter. For the last reported fiscal year 2026 ending Mar 31, 2026, VTGN reported annual earnings of -$69.7M, with 35.5% growth. The next VTGN earnings date is Aug 6, 2026.
Vistagen Therapeutics Earnings Reports & History FAQ
What were Vistagen Therapeutics's earnings last quarter?
On VTGN's earnings call on Jun 16, 2026, Vistagen Therapeutics (NASDAQ: VTGN) reported Q1 2026 earnings per share (EPS) of -$0.37, up 15.91% year over year. Total VTGN earnings for the quarter were -$16.27 million. In the same quarter last year, Vistagen Therapeutics's earnings per share (EPS) was -$0.44.
The next VTGN earnings date is Aug 6, 2026. Add VTGN to your watchlist to be reminded of Vistagen Therapeutics's next earnings date.
Is Vistagen Therapeutics profitable or losing money?
As of the last Vistagen Therapeutics earnings report, Vistagen Therapeutics is currently losing money. Vistagen Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$69.69 million, a 35.53% increase year over year.
What was VTGN's earnings growth in the past year?
As of Vistagen Therapeutics's earnings date in Jun 16, 2026, Vistagen Therapeutics's earnings has grown year over year. VTGN earnings in the past year totalled -$69.69 million.
What are Vistagen Therapeutics's earnings expectations?
The current EPS estimate for Vistagen Therapeutics's earnings report in Aug 6, 2026 is -$0.29.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.